Antileukemia activity of a natural killer cell line against human leukemias

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2859-2868

  Yan, Ying ^a,c   Steinherz, Peter ^a   Klingemann, Hans Georg ^b   Dennig, Dieter ^a   Childs, Barrett H ^a   McGuirk, Joseph ^a   O'Reilly, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOKINE ACTIVATED KILLER CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL TIME;

ANIMALS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LEUKEMIA; LEUKEMOID REACTION; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031782884     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Brittenden, J., Heys, S. D., Ross, J., and Eremin, O. Natural killer cells and cancer. Cancer (Phila.), 77: 1226-1243, 1996.
2. Robertson, M. J., and Ritz, J. Biology and clinical relevance of human natural killer cells. Blood, 76: 2421-2438, 1990.
3. Trincheri, G. Biology of natural killer cells. Adv. Immunol., 47: 187-375, 1989.
4. Pawelec, G. MHC-unrestricted immune surveillance of leukemia. Cancer Biother., 9: 265-288, 1994.
5. Lotzova, E., Savary, C. A., and Herberman, R. B. Induction of NK activity against fresh human leukemia in culture with interleukin 2. J. Immunol., 138: 2718-2727, 1987.
6. Melder, R. J., Whiteside, T. L., Vujanovic, N. L., Hiseridt, J. C., and Herberman, R. B. New approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res., 48: 3461-3469, 1988.
7. Yasumura, S., Lin, W., Hirabayashi, H., Vujanovic, N. L., Herberman, R. B., and Whiteside, T. L. Immunotherapy of liver metastases of human gastric carcinoma with IL2-activated natural killer cells. Cancer Res., 54: 3808-3816, 1994.
8. Vujanovic, N. L., Yasumura, S., Hirabayashi, H., Lin, W. C., Watkins, S., Herberman, R. B., and Whiteside, T. L. Antitumor activities of human IL2-activated natural killer cells in solid tumor tissues. J. Immunol., 154: 281-289, 1995.
9. Richards, S. J., and Scott, C. S. Human NK cells in health and disease: clinical, functional, phenotypic and DNA genotypic characteristics. Leuk. Lymphoma, 7(5-6): 377-399, 1992.
10. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G., and White, D. E. A. Progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316: 889-897, 1987.
11. Hercend, T., Reinherz, E. L., Meue, S., Schlossman, S. F., and Ritz, J. Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature (Lond.), 301: 158-160, 1983.
12. Yodoi, J., Teshigawarw, K., Nikaido, T., Fukui, K., Noma, T., Honjo, T., Takigawa, M., Sasaki, M., Minato, N., Tsudo, M., Uchiyama, T., and Maeda, M. TCGF(IL2)-receptor inducing factor(s). I. Regulation of IL2 receptor on a natural killer-like cell line (YT cells). J. Immunol., 134: 1623-1630, 1985.
13. Fernandez, L. A., Pope, B., Lee, C., and Zayed, E. Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line. Blood, 67: 925-930, 1986.
14. Robertson, M., Cochran, K., Cameron, C., Lee, J. M., Tantravahi R., and Ritz. J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp. Hematol., 24: 406-415, 1996.
15. Cesano, A., Visonneau, S., Cioé, L., Clark, S. C., and Santoli, D. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T-cell clone potentially useful in cancer therapy. Cancer Immunol. Immunother., 40: 139-151, 1995.
16. Cesano, A., Pierson, G., Visonneau, S., Migliaccio, A. R., and Santoli, D. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or-resistant leukemic targets. Blood, 87: 393-403, 1996.
17. Cesano, A., Visonneau, S., Cioé, L., Clark, S. C., Rovera, G., and Santoli, D. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Invest., 94: 1076-1084, 1994.
18. Cesano, A., Visonneau, S., Jeglum, K. A., Owen, J., Wilkinson, K., Carner, K., Reese, L., and Santoli, D. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res., 56: 3021-3029, 1996.
19. Gong, J., Maki, G., and Klingemann, H-G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia (Baltimore), 8: 652-658, 1994.
20. Klingemann, H-G., Wong, E., and Maki, G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol. Blood Marrow Transplant., 2: 68-75, 1996.
21. Mini, E., Moroson, B. A., Franco, C. T., and Bertino, J. R. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. Cancer Res., 45: 325-330, 1985.
22. Reisner, Y., Kapoor, N., Kirkpatrick, D., Pollack, M. S., Dupont, B., Good, R. A., and O'Reilly, R. J. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet, 2: 327-331, 1981.
23. Yan, Y., Ophira, S., McGuirk, J., Dennig, D., Fernandez, J., Jagiello, C., Hai, N., Collins, N., Steinherz, P., and O'Reilly, R. J. Growth pattern and clinical correlation of subcutaneously inoculated human primary acute leukemias in SCID mice. Blood, 88: 3137-3146, 1996.
24. Dokhelar, M. C., Wiels, J., and Lipinski, M. Natural killer cell activity in human bone marrow transplantation. Early appearance of peripheral natural killer activity in graft versus host disease. Transplantation (Baltimore), 31: 61-65, 1981.
25. Teichmann, J. V., Ludwig, W. D., and Thiel, E. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. Leuk. Res., 16: 287-298, 1992.
26. Teichmann, J. V., Ludwig, W. D., and Thiel, E. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cells activity - Analysis of 252 samples. Nat. Immun., 11: 117-132, 1992.
27. Pattengale, P. K., Sundstrom, C., Yu, A. L., and Leving, A. Lysis of fresh leukemic blasts by interferon-activated human nature killer cells. Nat. Immun. Cell Growth Regul., 3: 165-180, 1984.
28. Malnati, M. S., Peruzzi, M., Paker, K. C., Biddison, W. E., Ciccone, E., Moretta, A., and Long, E. O. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science (Washington DC), 267: 1016-1018, 1995.
29. Colonna, M., and Samaridis, J. Cloning of immunoglobilin-super-family members associated with HLA-C and HLA-B recognition by human natural killer cells. Science (Washington DC), 268: 405-408, 1995.
30. Litwin, V., Gumperz, J., Parham, P., Phillips, J. H., and Lanier, L. L. Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of target cell type. J. Exp. Med., 178: 1321-1336, 1993.
31. Pazmany, L., Mandelborim, O., Valés-Gómez, M., Davis, D. M., Reyburn, H. T., and Strominger, J. L. Protection from natural killer cell-mediated lysis by HLA-G expression of target cells. Science (Washington DC), 274: 792-795, 1996.
32. Helander, T. S., Carpén, O., Turunen, O., Kovanen, P. E., Vaheri, A., and Timonen, T. ICAM-2 redistributed by ezrin as a target for killer cells. Nature (Lond.), 382: 265-268, 1996.